COVID-19 patients who experience cytokine storms may make few memory B cells
Schematic of a germinal center in a lymph node showing proliferation and development of a B cell. Credit: CC BY-SA 3.0 - Billy10drs
The release of massive amounts of proteins called cytokines can lead to some of the most severe symptoms of COVID-19. When large numbers of immune cells release cytokines, this increases inflammation and creates a feedback loop in which more immune cells are activated and this is sometimes called a cytokine storm. An August 19 study in the journal Cell now suggests that high levels of some cytokines may also prevent people who are infected from developing long-term immunity as affected patients were observed to make very few of the type of B cells needed to develop a durable immune response.
“We’ve seen a lot of studies suggesting that immunity to COVID-19 is not durable because the antibodies decline over time,” says co-senior author Shiv Pillai, a professor at Harvard Medical School and member of the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard. “This study provides a mechanism that explains this lower-quality immune response.”
The investigators focused on germinal centers–the areas within the lymph nodes and spleens where B cells, the immune cells that produce antibodies, differentiate. Differentiation and changes in antibody genes are required to build immunity to an infectious agent.
“When we looked at the lymph nodes and spleens of patients who died from COVID-19, including some who died very soon after getting the disease, we saw that these germinal center structures had not formed,” says co-senior author Robert Padera, a pathology professor at Harvard. “We decided to determine why that’s the case.”
Because the disease was so new, animal models for studying COVID-19 infection were not yet available at the time they began their study. The researchers instead gained insights from previous studies involving mouse models of other infections that induce cytokine storm syndrome–a malaria model and one of bacterial infection in which germinal centers were lost.
In people with severe COVID-19, one of most abundant cytokines released is called TNF. In the infected mice, TNF appeared to block the formation of germinal centers. In previous cytokine storm models, when the mice were given antibodies to block TNF or had their TNF gene deleted, the germinal centers were able to form. When the researchers studied the lymph nodes of patients who had died of the disease, they found high levels of TNF in these organs. This led them to conclude that TNF may be preventing the germinal centers from forming in people with COVID-19 as well.
“Studies have suggested this lack of germinal centers happens with SARS infections,” Pillai says. “We even think this phenomenon occurs in some patients with Ebola, so it was not surprising to us.”
The researchers also studied blood and lymphoid tissue from people with active infections who were in different stages of COVID-19. They found that although germinal centers were not formed, B cells were still activated and appeared in the blood, which would allow the patients to produce some neutralizing antibodies. “There is an immune response,” Padera says. “It’s just not coming from a germinal center.”
“Without the germinal centers, there is no long-term memory to the antigens,” Pillai adds. He notes that studies of other coronaviruses that cause colds have suggested that someone can get infected with the same coronavirus three or four times in the same year.
The authors say despite their findings, they still believe a successful COVID-19 vaccine can be developed as it should not cause high levels of cytokines to be released.
Materials provided by Cell Press. Content may be edited for clarity, style, and length.